JDRF and PureTech have formed T1D Innovations to create and fund high-impact companies developing innovative Type 1 Diabetes (T1D) -related therapies
JDRF is one of the leading global organizations funding type 1 diabetes (T1D) research. JDRF’s goal is to progressively remove the impact of TID from people’s lives until we achieve a world without T1D.
JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D.
As the largest charitable supporter of T1D research, JDRF is currently sponsoring $530 million in scientific research in 17 countries. In fiscal year 2013 alone, JDRF provided more than $106 million to T1D research. More than 80 percent of JDRF’s expenditures directly support research and research-related education. In 2012, Forbes magazine named JDRF one of its five All-Star charities, citing the organization’s efficiency and effectiveness.For more information, visit www.jdrf.org.
PureTech is a science and technology development company.
Alongside top scientist-inventors and industry partners, PureTech deconstruct the problem & solve it in an entirely new way. PureTech’s pipeline of over a dozen products includes a number of clinical stage programs. For more information, visit www.puretechventures.com.
Joslin Research comprises the most comprehensive and productive effort in diabetes research under one roof anywhere in the world. With 30‐plus faculty‐level investigators, Joslin researchers focus on unraveling the biological, biochemical and genetic processes that underlie the development of type 1 and type 2 diabetes and related complications.
Joslin research is highly innovative and imaginative, employing the newest tools in genetics, genomics and proteomics to identify abnormalities that may play a role in the development of diabetes and its complications. Joslin Clinic patients, and others with diabetes, have the option of participating in clinical trials at Joslin to help translate basic research into treatment innovations.
Joslin has one of the largest diabetes training programs in the world, educating 150 M.D. and Ph.D. researchers each year, many of whom go on to head diabetes initiatives at leading institutions all over the globe. For more information, visit www.joslinresearch.org.
T1D Exchange is a non-profit organization with the mission to improve outcomes of people touched by type 1 diabetes by accelerating the discovery of new approaches to research and development. It connects the disparate stakeholders in the type 1 diabetes community by combining the critical components of traditional clinical research with the expanding fields of health information technology and social networking.
T1D Exchange evolved as a solution to mitigate barriers and inefficiencies for type 1 diabetes research and development. It is a personalized exploration platform anchored in health informatics: T1D Exchange consists of Glu, an interactive website with mobile capabilities for patients and caregivers; a network of 69 clinics across the United States; and a biorepository comprising clinically annotated patient biological samples. T1D Exchange was founded in 2011 through a grant from The Leona M. and Harry B. Helmsley Charitable Trust. More information is available at www.t1dexchange.org.
T1D Innovations brings together some of the world’s leading Type 1 diabetes foundations, research organizations, and patient engagement groups with top strategic and entrepreneurial collaborators to accelerate the transition of high impact technologies across the biomedical “valley of death.” T1D Innovations goes beyond impact investing to create a vehicle to conceptualize, found, and grow T1D startups from the ground up.
Scientific Advisory Board
Richard Insel, M.D.
Scientific Advisory Board
Richard Insel, M.D. oversees the research strategy at the JDRF, the worlds’ largest funder of type 1 diabetes research, with an annual research budget over $100M focused on curing, treating, and preventing type 1 diabetes. Prior to joining JDRF in 2003, Dr. Insel was founding Director of the Center for Human Genetics and Molecular Pediatric Disease and Professor of Pediatrics and Microbiology/ Immunology at the University of Rochester Medical Center. During his 26-year affiliation with the University of Rochester Medical Center, he held several positions including, Director of the Strong Children’s Research Center, Chief of the Division of Pediatric Immunology, Allergy, and Rheumatology, and Acting Chair of Pediatrics. His research program at the University focused on immune responses to bacterial vaccines and B lymphocyte immunity. Dr. Insel was a scientific co-founder and served as a member of the Board of Directors of Praxis Biologics, a biotechnology company that developed bacterial conjugate vaccines. Dr. Insel received pediatric and immunology training at Boston Children’s Hospital, Harvard Medical School, St. Mary’s Hospital, London, England, and the Center for Disease Control.
Jay J. Schnitzer, M.D., Ph.D.
Jay J. Schnitzer is the Health and Human Services (HHS) Portfolio Director at MITRE. Before joining MITRE, Dr. Schnitzer was the Director of the Defense Sciences Office (DSO) at the Defense Advanced Research Projects Agency (DARPA). Previously, Dr. Schnitzer was at Boston Scientific Corporation as Chief Medical Officer and Senior Vice President.
He graduated from Worcester Polytechnic Institute in Worcester, MA, with a B.S. in chemical engineering (high distinction) in 1973. In 1983, he received a Ph.D. in chemical engineering from the Massachusetts Institute of Technology, and an M.D. (cum laude) from Harvard Medical School. Dr. Schnitzer completed his residency-training program in general surgery at the Brigham and Women’s Hospital, Boston (1983-1988), followed by a fellowship in pediatric surgery at Children’s Hospital, Boston (1989-1991).
Other credentials include: board certification (and recertification) in general surgery and pediatric surgery; Fellow of the American College of Surgeons and the American Academy of Pediatrics; provider and instructor in Advanced Trauma Life Support, Advanced Burn Life Support, and Advanced Trauma Operative Management; and provider in Advanced Cardiac Life Support and Pediatric Advanced Life Support. His memberships in national and international societies include, among others, the American Surgical Association, Association for Academic Surgery, American Pediatric Surgical Association, Surgical Biology Club I, Boston Surgical Society, American Burn Association, New England Surgical Society, and the British Association of Pediatric Surgeons.
Charles J. Queenan III
Charles J. Queenan III is a Partner at T1D Innovations. Mr. Queenan’s experience with diabetes research and innovation spans over 20 years. He served for six years on the JDRF International Board, as a member of its Executive Committee and Chair of Research, and remains on its Board of Chancellors. Mr. Queenan was Founder and Managing Director of Strategic Resolve, LLC, where he provided management consulting services to emerging life sciences companies. Previously, Mr. Queenan was Senior Vice President, New Ventures at JDRF, EVP and Chief Business Officer of Amaranth Bio, Inc. (an early-stage regenerative medicine company developing a cellular therapy for diabetes), and Senior Vice President of the international management consulting firm of PHB/Hagler Bailly. Mr. Queenan received his A.B. in chemistry (summa cum laude) and B.E. and M.E. degrees in chemical engineering from Dartmouth College and an MBA from Carnegie Mellon. Mr. Queenan currently serves on the Joslin Diabetes Center Business Advisory Board. His daughter, now 25, was diagnosed with T1D at the age of 3.
John L. Brooks, III
Mr. Brooks is the President and Chief Executive Officer of the Joslin Diabetes Center, the world’s leading diabetes research, clinical care, and education organization. Joslin’s global mission is to prevent, treat, and cure diabetes and its complications.
Mr. Brooks has co-founded four life sciences companies, including Insulet, a disruptive insulin delivery company. He had been a principal of Healthcare Capital Consulting LLC, which advised early-stage life sciences companies, and he was a founder of Prism Venture Partners, a venture capital firm.
Previously, he was a general manager at Pfizer/Valleylab, where he was responsible for Pfizer’s Hospital Products Group’s minimally invasive surgery and new medical technologies business. As President/General Manager at Pfizer/Strato, he led the growth of a rapidly evolving vascular access medical device business.
He holds an M.S. in Business and a B.B.A. cum laude from the University of Massachusetts at Amherst and he is a Certified Public Accountant.
Mr. Steinberg is a Partner at PureTech Ventures. As a member of PureTech, Mr. Steinberg has served as founding CEO and board member of portfolio companies Enlight Biosciences, Endra Inc., Vedanta Biosciences, Entrega Biosciences and Knode Inc. He also served as Chief Business Officer of portfolio company Follica, Inc., and VP of Operations for portfolio company Satori Pharmaceuticals.
Previously, he was a strategy consultant with the Boston Consulting Group and Vertex Partners, focusing on R&D and product strategy and strategic alliances for Fortune 500 pharmaceutical and biotechnology clients.
Mr. Steinberg also worked as a research associate in Procter and Gamble Pharmaceuticals' R&D organization. He received his BA in Biology with distinction from Cornell University and graduated with high honors from the University of Chicago Booth School of Business with an MBA in strategy and finance. Mr. Steinberg is also a member of the UChicago Tech Innovation Fund Advisory Committee.
Ketki Karanam, Ph.D.
Dr. Karanam is a Senior Analyst at PureTech Ventures, and is part of the Enlight Immersive Health team. She completed her doctoral work at Harvard University in the Department of Systems Biology, focusing on DNA repair in cancer cells.
While a graduate student, Dr. Karanam served as a Fellow with the Harvard Office of Technology Development, where she worked on translating emerging life science technologies into commercial healthcare products.
Dr. Karanam received her B.S. in Microbiology from Pune University, India and her M.S. in Biological Sciences from the Indian Institute of Science, during which time she held the national JNCASR and Rajiv Gandhi Science Talent fellowships. She received her PhD in Systems Biology from Harvard.
James Mutamba, Ph.D.
Dr. Mutamba is an Associate at PureTech, and is part of the Mandara and Vedanta teams. Prior to joining PureTech, Dr. Mutamba was a strategy consultant at ClearView Healthcare Partners and played multiple roles in research and product development at Pathogenica, Inc., a biotech start up.
Dr. Mutamba completed his graduate work at MIT in the Department of Biological Engineering, focusing on the relationship between inflammation-derived reactive species and cancer.
During his graduate work, Dr. Mutamba received a Medtronic Graduate Fellowship and several Environmental Mutagen Society awards. He also completed coursework at the MIT Sloan School of Management. Dr. Mutamba received his B.S. in Biochemistry from UNCG, and his Ph.D. from MIT.
Area of Focus
Beta Cell Restoration
Beta Cell Restoration
Technologies that restore normal insulin production lost as a result of the autoimmune destruction of beta cells in the pancreas. Approaches include therapies that regenerate new insulin producing cells, slow the destruction of existing beta cells and/or reprogram other healthy cells in the body to make insulin.
Beta Cell Therapies
Beta Cell Therapies
Technologies that replace the insulin producing cells lost as a result of autoimmune destruction by implantation of new ones, either in combination with immune therapies or together with immune barriers. Approaches include transplantation of islets or islet-precursors generated from stem cells, transplantation of encapsulated insulin producing cells derived from animals such as pigs, and therapeutics that enhance transplanted cell survival and proliferation.
Technologies that prevent or halt the autoimmune process that causes T1D, or prevent it from reoccurring. Approaches include antigen-specific vaccines that prevent or slow the progression of diabetes in at-risk populations, therapies that correct imbalances in the human immune system that lead to autoimmunity (e.g. by altering the composition of the human microbiome), therapies that target islet inflammation and beta cell stress, and therapies that either destroy the cells that target insulin producing cells or enhance the population of cells that enable proper regulation of the immune system.
Technologies that mimic the function of a healthy pancreas by combining insulin infusion together with continuous monitoring of glucose homeostasis. Technologies include pump technologies (for example, bihormonal pumps that deliver insulin along with other hormones such as amylin or glucagon, and infusion technologies that enable rapid insulin delivery), advanced algorithms to enable fully automated closed loop insulin control, more accurate and reliable continuous monitoring devices, and mobile and electronic applications that improve wearability, convenience and comfort.
Technologies that more closely mimic physiologic regulation of blood glucose, for example, with glucose responsive insulins, faster acting insulins, co-administration of therapeutics that correct hypoglycemic unawareness, and replacement of hormones in addition insulin that are also lost or dysregulated as a result of diabetes.
Prevention and Treatment of Complications
Technologies that prevent and/or treat complications of diabetes, including especially eye, kidney and nerve disease. Approaches include technologies that allow early diagnosis and monitoring of the progression of disease, therapeutics that ameliorate the underlying cause of disease, and factors that confer resistance to complications.